| Title: | Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer’s disease |
|---|
| Authors: | ID Benussi, Alberto (Author)
ID Agosta, Federica (Author)
ID Alfano, Alba Rosa (Author)
ID Antico, Antonio (Author)
ID Bellelli, Giuseppe (Author)
ID Bonanni, Laura (Author)
ID Bottini, Gabriella (Author)
ID Bozzali, Marco (Author)
ID Brignoli, Ovidio (Author)
ID Bruno, Giuseppe (Author)
ID De Leo, Diego (Author) |
|---|
| Files: |  RAZ_Benussi_Alberto_2025.pdf (1,22 MB)
MD5: D149BC4E6F34CD1710EA1D35FEE4FDC4
 https://link.springer.com/article/10.1007/s10072-025-08576-y
|
|---|
| Language: | English |
|---|
| Work type: | Article |
|---|
| Typology: | 1.02 - Review Article |
|---|
| Organization: | IAM - Andrej Marušič Institute
|
|---|
| Abstract: | This joint Position Paper, developed by the Italian Expert Panel on Alzheimer convened by the Italian Society of Neurology with participation from multiple scientific societies, outlines strategic guidelines for reorganizing the patient journey in the era of anti-amyloid monoclonal antibodies for Alzheimer’s disease. Emphasizing a multidisciplinary and integrated approach, the document recommends a patient journey that begins with early identification of cognitive impairment by General Practitioners, continues with specialized assessments at Memory and Dementia Centres, and leads, in carefully selected cases, to initiation of anti-amyloid monoclonal antibody therapy. It advocates the rational use of diagnostic tools, including plasma and cerebrospinal fluid biomarkers, advanced neuroimaging (MRI and PET), and genetic profiling (ApoE genotyping), not only to identify eligible patients but also to stratify those requiring alternative care strategies. The paper further defines minimum requirements for the accreditation of prescribing and infusion centres, highlighting the clinical competencies, structural resources, and inter-professional communication protocols necessary to ensure safety and appropriateness. Recognizing both the therapeutic potential and the organizational challenges associated with anti-amyloid monoclonal antibodies, the document aims to guide healthcare policymakers, institutions, and practitioners toward a coordinated reorganization of the diagnostic-therapeutic pathway, ensuring the safe and effective use of these treatments and ultimately improving outcomes and quality of care for individuals with Alzheimer’s disease. |
|---|
| Keywords: | Alzheimer’s disease, disease-modifying therapies, anti-amyloid monoclonal antibodies, biomarkers, clinical implementation |
|---|
| Publication version: | Version of Record |
|---|
| Publication date: | 17.10.2025 |
|---|
| Year of publishing: | 2025 |
|---|
| Number of pages: | str. 6875-6894 |
|---|
| Numbering: | Vol. 46, iss. 12 |
|---|
| PID: | 20.500.12556/RUP-22301  |
|---|
| UDC: | 616.892.3 |
|---|
| ISSN on article: | 1590-3478 |
|---|
| DOI: | 10.1007/s10072-025-08576-y |
|---|
| COBISS.SI-ID: | 262538243 |
|---|
| Publication date in RUP: | 22.12.2025 |
|---|
| Views: | 142 |
|---|
| Downloads: | 2 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Average score: | (0 votes) |
|---|
| Your score: | Voting is allowed only for logged in users. |
|---|
| Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
